Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
WALTHAM, Mass., April 06, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the 15th Annual Needham Healthcare Conference in New York City. The company is scheduled to present on Wednesday, April 13, 2016 at 12:10 pm ET and will provide a corporate update followed by a question and answer session.
A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Headquartered in Waltham, MA, AMAG possesses a diverse portfolio of products to support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, the company also helps families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood conditions and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Linda Lennox Vice President, Investor Relations 617-498-2846
